An interventional study of TURP and UroLift in Prostate Cancer, sponsored by Royal Marsden NHS Foundation Trust. Recruiting at 3 sites in United Kingdom. Open to male participants. Per ClinicalTrials.gov, last updated 2023-09-01.
Sponsored by Royal Marsden NHS Foundation Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust — 8 open to participants now, 10 under way, 1 of them phase 3. Prostatic Neoplasms · Royal Marsden NHS Foundation Trust.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, this one is the 10th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 9 with no phase, and was the 13th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust are open now, in 2 countries. Recruiting first, the newest first:
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18–100 · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in Canada, United Kingdom
Ages 18+ · Men only
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Men only · Healthy volunteers
Royal Marsden NHS Foundation Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3
First in 2000; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 45 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 81 across the 14 interventional studies, 100 across the 7 observational. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Marsden NHS Foundation Trust is the lead sponsor of 275 studies on the registry; 54 are open to participants now.
4 of the studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06638541Royal Marsden NHS Foundation TrustDose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions | 2027-01-01 |
| NCT06019676Royal Marsden NHS Foundation TrustImpact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients | 2027-04-01 |
| NCT07870707Royal Marsden NHS Foundation TrustProstate Cancer in UK Prisons: A Retrospective Data Analysis | 2027-08-03 |
| NCT07741929Royal Marsden NHS Foundation TrustPatient and Provider Perspectives on Genetic Risk Profiling | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Prostatic Neoplasms by Royal Marsden NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prostate cancer affects 1 in 8 men and in the UK approximately 14,000 men are treated with radiotherapy.
Around half of men diagnosed with prostate cancer will also have an enlarged prostate making it difficult to pass urine. When having radiotherapy, the prostate swells further which can lead to complete blockage of urine flow (urine retention), sepsis and kidney failure in severe cases. Radiotherapy itself can also cause urinary symptoms meaning that some patients can continue to have difficulty passing urine long after their cancer treatment finishes. Around a third of patients will need an operation to shrink their prostate before radiotherapy to prevent these possible short and long-term problems.
The standard operation is a transurethral resection of prostate (TURP). This involves cutting a channel through the prostate to improve urine flow.
This will be compared with a newer procedure known as UroLift. During UroLift, clips are inserted into the water pipe to pin back the prostate to widen the channel and improve urine flow. Which treatment is more acceptable to patients and gives better outcomes has never been tested before in men having radiotherapy for prostate cancer.
The study will help us to understand how the treatments impact on a patient's quality of life and understand what matters most to patients.
The results of this feasibility study will help us design a bigger study to assess TURP and UroLift in a larger group of patients across different hospitals. This research will help future patients make decisions about prostate cancer treatment choices that can affect their long-term well-being.
Prostate radiotherapy can cause lower urinary tract symptoms (LUTS) such as urinary frequency, difficulty starting a urine stream or feelings of incomplete emptying. 50% of men aged over 60 years may have pre-existing LUTS from bladder outflow obstruction (BOO) due to prostatic enlargement.
The short-term complications of untreated BOO in the context of prostate radiotherapy, although relatively rare, can be disastrous, leading to urinary retention, sepsis and renal failure. In the long-term, urinary symptoms and complications can continue to worsen. Patients with low flow rates pre-radiotherapy are at highest risk of urinary retention and are often offered transurethral resection of prostate (TURP) prior to radiotherapy. An urgent transurethral resection of prostate (TURP) either during or post radiotherapy may significantly disrupt the completion of the treatment and compromise outcomes, both oncological and functional. Case studies suggest that when patients undergo a TURP to treat prostate enlargement after radiotherapy, the risk of incontinence is much higher than surgery before radiotherapy. Therefore, for radiotherapy to safely go ahead, BOO due to an enlarged prostate must first be addressed. UroLift is a newer, minimally invasive alternative to TURP, approved by NICE for use in BPH and available in over 100 trusts nationally. A growing body of evidence including three meta-analyses supports its use in benign disease.
UroLift has not been trialled in patients undergoing prostate radiotherapy with coexisting LUTS. A subgroup analysis performed on retrospective data suggested that patients who had previously undergone prostate radiotherapy experienced symptom relief without an increase in adverse events.
The purpose of this trial is to produce a protocol for a randomised controlled evaluation of clinical and cost effectiveness of UroLift in comparison to TURP for men due to receive radiotherapy as treatment for prostate cancer. At the end of this study, we will understand whether such a trial is acceptable to all stakeholders, is methodologically robust and thus feasible. Furthermore, we will be able to report pilot findings for safety and efficacy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Transurethral Resection of Prostate
Procedure: TURP
UroLift
Procedure: UroLift
TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.
UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
Recruitment rate (number of patients enrolled)
We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena
Time frame: Number of patients recruited measured at 3 months
Recruitment rate (number of patients enrolled)
We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena
Time frame: Number of patients recruited measured at 6 months
Recruitment rate (number of patients enrolled)
We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena
Time frame: Number of patients recruited measured at 9 months
Recruitment rate (number of patients enrolled)
We will evaluate whether it is possible to recruit patients to an RCT comparing standard treatment with a new treatment untested in the cancer arena
Time frame: Number of patients recruited measured at 12 months
Retention rate
We will assess the proportion of patients who will complete the trial protocol
Time frame: End of study (24 months)
Acceptability of intervention
The Research Team will carry out 12 in-depth interviews. Using the Theoretical Framework of Acceptability(19), affective attitudes, burden, ethicality, intervention coherence, opportunity costs and perceived effectiveness will be assessed
Time frame: End of study (24 months)
Change from baseline in patient reported outcomes as assessed by the Extended Prostate Cancer Index Composite-50 (EPIC-50)
The EPIC-50 is a validated questionnaire for measuring health related quality of life
Time frame: Baseline, 6 weeks and three months post intervention
Change from baseline in patient reported outcomes as assessed by the UCLA Prostate Cancer Index (UCLA-PCI)
The UCLA-PCI is a validated questionnaire for measuring health related quality of life
Time frame: Baseline, 6 weeks and three months post intervention
Change from baseline in patient reported outcomes as assessed by the International Consultation on Incontinence Questionnaire-Urinary Incontinence (ICIQ-UI)
The ICIQ-UI is a validated questionnaire s a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence
Time frame: Baseline, 6 weeks and three months post intervention
Change from baseline in patient reported outcomes as assessed by the EuroQol EQ-5D
The EQ-5D is a validated questionnaire for measuring health related quality of life
Time frame: Baseline, 6 weeks and three months post intervention
Change from baseline in patient reported outcomes as assessed by the Couples Illness Communication Scale (CICS)
The CICS is a validated questionnaire for assessing illness-related couple communication
Time frame: Baseline, 6 weeks and three months post intervention
Change post surgery & post radiotherapy in patient reported outcomes as assessed by the patient global impression of improvement (PGI)
The PGI is a validated single item self reported scale to assess patient reported post-operative improvement in condition
Time frame: 6 weeks and three months post intervention
Change from baseline in patient reported outcomes as assessed by the International Prostate Symptom Score (IPSS)
The IPSS is a validated questionnaire for measuring the severity of urinary symptoms and overall quality of life
Time frame: Baseline, 6 weeks and three months post intervention
Post treatment functional assessment of cancer therapy prostate (FACT-P)
The FACT-P is a multidimensional, self-reported quality of life instrument consisting of 27 core items that assess participant function in 4 domains: physical, social/family, emotional, functional well-being, and supplemented by 12 site-specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert-type scale, and then combined to produce subscale scores for each domain. Total subscale score range for physical well-being domain is from 0 (worst response) to 28 (best response), where higher score indicate better quality of life.
Time frame: Three months post intervention
Health related quality of life questionnaires
collected and assessed for appropriateness, usability and completeness for both arms 3 months post radiotherapy treatment
Time frame: End of study (24 months)
Safety
30 day surgical morbidity rates will be collected with respect but not limited to infection, urinary retention and bleeding.
Time frame: 30 days post surgery
Efficacy of procedure
Improvement in baseline IPSS score
Time frame: End of study (24 months)
Efficacy of procedure
Improvement in baseline Urine flowmetry (measured by increased maximum flow rate)
Time frame: End of study (24 months)
Efficacy of procedure
Improvement in baseline Urine flowmetry (measured by post void residual)
Time frame: End of study (24 months)
Cost of intervention
Information on costs of the two interventions
Time frame: End of study (24 months)
Re-Operation rate
Rate of re-operation for technical failure to reduce outflow obstruction
Time frame: End of study (24 months)
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for May 2024, 12 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 12 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Marsden NHS Foundation Trust →